[{"orgOrder":0,"company":"Kemwell Biopharma Private Limited","sponsor":"RevOpsis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"RO-104","moa":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Kemwell Biopharma Private Limited","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Kemwell Biopharma Private Limited \/ RevOpsis Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Kemwell Biopharma Private Limited \/ RevOpsis Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Kemwell Biopharma Private Limited

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : Through the partnership, RevOpsis is well-positioned to advance the clinical development of RO-104, a first-in-class lead candidate for the treatment of neovascular age-related macular degeneration.

                          Brand Name : RO-104

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          June 17, 2024

                          Lead Product(s) : RO-104

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : IND Enabling

                          Sponsor : RevOpsis Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank